# Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

> **NCT06039891** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 55 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Nimotuzumab、Tislelizumab

## Key facts

- **NCT ID:** NCT06039891
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2024-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06039891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06039891, "Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06039891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*